Michael Serzan, MD

Michael Serzan, MD

Dana-Farber Cancer Institute

Latest Content

Dr. Michael Serzan and Dr. Sumanta Pal discuss adjuvant immunotherapy in renal cell carcinoma at OncUpdates, with a city skyline and Ferris wheel in the background.

Conferences

06/22/2026

Adjuvant Immunotherapy in RCC: Insights From RAMPART

Sumanta Pal, MD, FASCOMichael Serzan, MD
Medical professional holding a stethoscope, focusing on the evolving landscape of refractory renal cell carcinoma in cancer treatment.

GU Oncology

05/14/2026

The Evolving Landscape of Refractory Renal Cell Carcinoma 

Michael Serzan, MD
Advanced renal cell carcinoma research on HIF-2α inhibition featuring Dr. Michael Serzan and Dr. Toni Choueiri, with a cityscape background, highlighting innovative cancer treatment developments.

RCC

03/16/2026

Positive Trials for Belzutifan in Earlier Treatment Lines for RCC

Michael Serzan, MDToni Choueiri, MD
Radiotherapy strategies in metastatic clear cell renal cell carcinoma featuring Dr. Shreyas Kalantri and Dr. Michael Serzan with a cityscape background.

RCC

03/15/2026

Radiotherapy Strategies in Metastatic Clear Cell Renal Cell Carcinoma

Michael Serzan, MDShreyas Kalantri, MD
PSA test blood sample for prostate cancer detection in laboratory setting.

GU Oncology

11/06/2025

ESMO 2025 Updates in Prostate Cancer: Advances in Radioligand, Genomic, and AR-Targeted Therapies

Michael Serzan, MD
High-tech illustration of a human prostate gland with medical visualization elements, symbolizing advanced prostate cancer research and treatment options.

Conferences

06/11/2025

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Albert Jang, MDMichael Serzan, MD
Advances in oncology research and treatment discussed at OncUpdates, featuring medical professionals sharing insights on cancer therapies and breakthroughs, highlighting the latest in cancer care.

Conferences

06/11/2025

Highlights From the AMPLITUDE Study at ASCO 2025

Albert Jang, MDMichael Serzan, MD
Alcohol-reinforcement-removal-urinary-kidney-cancer-treatment-therapy-illustration.

Conferences

06/11/2025

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Albert Jang, MDMichael Serzan, MD